Access Program for Mitomycin Solution for Kidney and Urinary Tract Cancer
Sponsor: UroGen Pharma Ltd.
Expanded Access
Sponsor score: 60
Inactive
ClinicalTrials ID:NCT05494411
This program allows patients in certain countries to access JELMYTO, a treatment for kidney and urinary tract cancer, before it is officially approved in those areas. It is available for patients who have no other treatment options left.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The program is designed to provide access to JELMYTO, a treatment for kidney and urinary tract cancer, for patients in specific countries where the drug is not yet approved. This is done through requests made by doctors or healthcare providers on behalf of patients who have tried all other available treatments without success.
Eligibility Criteria
Inclusion Criteria
- Patients who are considered suitable for JELMYTO treatment and are expected to benefit from it, as determined by their doctor.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.